Literature DB >> 29214477

Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta university hospitals: a single-center study.

Ghada Abdelmoemen1, Samy Abdelkader Khodeir2, Sabry Abou-Saif3, Abdelrahman Kobtan3, Sherief Abd-Elsalam4,5.   

Abstract

Occult hepatitis C virus infection (OCI) is a newly defined type of infection by the chronic hepatitis virus (HCV) distinguished by the existence of HCV RNA in liver tissue and/or peripheral blood mononuclear cells (PBMCs) in patients whose plasma are devoid of both positive serology and RNA. Patients on maintenance hemodialysis evince a higher HCV prevalence than the general population due to high nosocomial transmission by the dialysis units. We investigated the prevalence of occult HCV infection in patients attending our university hemodialysis centers for maintenance hemodialysis. Sixty-two CHD patients negative for serum HCV tests were enrolled in the study. PMNCs were tested by real-time PCR for the presence of HCV RNA. For the 62 patients, the average duration since starting dialysis was 32.7 months and the mean (SD) alanine transaminase and aspartate transaminase were 25.74 ± 9.75 and 28.81 ± 11.32 IU/l, respectively. Out of the 62 CHD patients negative for serum anti-HCV and HCV RNA patients, only three (4.84%) were shown to have HCV RNA in their PBMCs implying the diagnosis of OCI; their viral load range was 1.24-4.15 IU/ml. All three OCI-proven patients gave no history of hepatic disease. In this study, we found that patients considered to be free of HCV can have HCV replicating in their PBMCs. This awareness points to the possibility of HCV being transmitted from apparently uninfected persons. A positive HCV RNA detection in PBMCs is dependable in determining OCI among high-risk subjects particularly when a liver biopsy is not an option. HCV transmission can occur through hemodialysis units signaling incorrect application of infection control measures in our Egyptian dialysis units. Additional studies on hemodialysis patients are necessary to realize the true magnitude of OCI among this patient group and to highlight the importance of incorporating HCV viral assays in PBMCs into the diagnostic algorithm.

Entities:  

Keywords:  Anti-HCV; HCV; HCV RNA; Hemodialysis; Occult hepatitis C; PBMCs; Peripheral blood mononuclear cells; Prevalence

Mesh:

Substances:

Year:  2017        PMID: 29214477     DOI: 10.1007/s11356-017-0897-y

Source DB:  PubMed          Journal:  Environ Sci Pollut Res Int        ISSN: 0944-1344            Impact factor:   4.223


  36 in total

1.  Occult hepatitis C virus infection in hemodialysis.

Authors:  Fabrizio Fabrizi; Paul Martin
Journal:  J Am Soc Nephrol       Date:  2008-11-19       Impact factor: 10.121

2.  Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment.

Authors:  Inmaculada Castillo; Elena Rodríguez-Iñigo; Juan Manuel López-Alcorocho; Margarita Pardo; Javier Bartolomé; Vicente Carreño
Journal:  Clin Infect Dis       Date:  2006-10-05       Impact factor: 9.079

3.  Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus.

Authors:  T N Q Pham; C S Coffin; N D Churchill; S J Urbanski; S S Lee; T I Michalak
Journal:  J Viral Hepat       Date:  2011-03-01       Impact factor: 3.728

Review 4.  Occult hepatitis C virus infection: a new form of hepatitis C.

Authors:  Vicente Carreño
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

5.  Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease.

Authors:  Farah Bokharaei-Salim; Hossein Keyvani; Seyed Hamid Reza Monavari; Seyed Moayed Alavian; Zahra Madjd; Mohssen Nassiri Toosi; Amir Houshang Mohammad Alizadeh
Journal:  J Med Virol       Date:  2011-06       Impact factor: 2.327

6.  Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients.

Authors:  Fahri Yakaryilmaz; Oguz Alp Gurbuz; Sefa Guliter; Ali Mert; Yildiran Songur; Tarkan Karakan; Hatice Keles
Journal:  Ren Fail       Date:  2006       Impact factor: 2.606

Review 7.  Hepatitis C in dialysis units: the Saudi experience.

Authors:  Ayman Karkar
Journal:  Hemodial Int       Date:  2007-07       Impact factor: 1.812

8.  Prevalence of hepatitis C antibodies among hemodialysis patients in the Western province of saudi arabia.

Authors:  F A Shaheen; S O Huraib; R Al-Rashed; A Aldrees; M Arif; M Al Jeffry; M A Tashkandy; M Safwat
Journal:  Saudi J Kidney Dis Transpl       Date:  1995 April-June

9.  Occult hepatitis C virus infection among Egyptian hemodialysis patients.

Authors:  Soha S Abdelrahim; Rasha Khairy; Mona Abdel-Monem Esmail; Mahmoud Ragab; Mohamed Abdel-Hamid; Sayed F Abdelwahab
Journal:  J Med Virol       Date:  2016-01-18       Impact factor: 2.327

10.  Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: effect of time, initiating HCV prevalence studies and adoption of isolation measures.

Authors:  Guillermina Barril; Juan Antonio Traver
Journal:  Antiviral Res       Date:  2003-10       Impact factor: 5.970

View more
  9 in total

1.  Global prevalence of occult hepatitis C virus: A systematic review and meta-analysis.

Authors:  Donatien Serge Mbaga; Sebastien Kenmoe; Jacky Njiki Bikoï; Guy Roussel Takuissu; Marie Amougou-Atsama; Etienne Atenguena Okobalemba; Jean Thierry Ebogo-Belobo; Arnol Bowo-Ngandji; Martin Gael Oyono; Jeannette Nina Magoudjou-Pekam; Ginette Irma Kame-Ngasse; Alex Durand Nka; Alfloditte Flore Feudjio; Cromwel Zemnou-Tepap; Elie Adamou Velhima; Juliette Laure Ndzie Ondigui; Rachel Audrey Nayang-Mundo; Sabine Aimee Touangnou-Chamda; Yrene Kamtchueng Takeu; Jean Bosco Taya-Fokou; Chris Andre Mbongue Mikangue; Raoul Kenfack-Momo; Cyprien Kengne-Ndé; Carole Stephanie Sake; Seraphine Nkie Esemu; Richard Njouom; Lucy Ndip; Sara Honorine Riwom Essama
Journal:  World J Methodol       Date:  2022-05-20

2.  The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting.

Authors:  Gina Gamal Naguib; Tari George Michael; Yehia Elshazly; Maha Magdy Wahdan; Aya Mostafa; Ossama Ashraf Ahmed; Hany Dabbous; Heba Ismail Saad Aly; Mohamed Kamal Shaker; Hosam Samir Elbaz; Magdy El-Serafy; Wahid Doss; Sherief Abd-Elsalam; Manal Hamdy El-Sayed
Journal:  Virusdisease       Date:  2021-07-27

3.  Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure.

Authors:  Yousry Esam-Eldin Abo-Amer; Rehab Badawi; Mohamed El-Abgeegy; Heba Fadl Elsergany; Ahmed Abdelhaleem Mohamed; Sahar Mohamed Mostafa; Hatem Samir Alegaily; Shaimaa Soliman; Sally Elnawasany; Sherief Abd-Elsalam
Journal:  Adv Virol       Date:  2020-07-24

4.  Evaluation of Serum and Gene Expression of Galectin-4, Interleukin-27, and Complement-7 in Hepatitis C Virus-Infected Egyptian Patients.

Authors:  Marwa S Abdel-Tawab; Hanan H Fouad; Dalia A Omran; Aml E Abdou; Shaimaa Mohamed Zaied; Alaa A Mohamed
Journal:  Biomed Res Int       Date:  2020-12-15       Impact factor: 3.411

5.  Regulatory polymorphism of CXCL10 rs1439490 in seronegative occult hepatitis C virus infection.

Authors:  Xu Wang; Song Wang; Zhen-Hua Liu; Wen-Qian Qi; Qian Zhang; Yong-Gui Zhang; De-Rong Sun; Yan Xu; Hong-Guang Wang; Zhong-Xie Li; Xian-Ling Cong; Ping Zhao; Chang-Yu Zhou; Jiang-Bin Wang
Journal:  World J Gastroenterol       Date:  2018-05-28       Impact factor: 5.742

6.  Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience.

Authors:  Sherief Abd-Elsalam; Yousry Esam-Eldin Abo-Amer; Mohamed El-Abgeegy; Samah A Elshweikh; Heba Fadl Elsergany; Rehab Ahmed; Mahmoud Elkadeem; Nehad Hawash; Shaimaa Soliman; Rehab Badawi; Ayman Mohammed Abdou Elguindy; Moataz Yousry Soliman; Ahmed Abdelhaleem Mohmed; Loai Mansour
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

7.  Seroprevalence occurrence of viral hepatitis and HIV among hemodialysis patients.

Authors:  Inass Mahmood Abid Kamal; Batool Mutar Mahdi
Journal:  Ann Med Surg (Lond)       Date:  2018-03-16

Review 8.  Occult Infection with Hepatitis C Virus: Looking for Clear-Cut Boundaries and Methodological Consensus.

Authors:  Anna Wróblewska; Krzysztof Piotr Bielawski; Katarzyna Sikorska
Journal:  J Clin Med       Date:  2021-12-14       Impact factor: 4.241

9.  Prevalence and Predominant Genotype of Hepatitis C Virus Infection and Associated Risk Factors among Pregnant Women in Iran.

Authors:  Fatemeh Farshadpour; Reza Taherkhani; Farkhondeh Bakhtiari
Journal:  Biomed Res Int       Date:  2021-09-18       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.